ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1381

Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1019

Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease

RA – Animal Models Poster (1014–1021)

8:30AM-10:30AM: Abstract Number: 0997

Citrullinated Vimentin Induces Epigenetic Memory of the Innate Immune System

Innate Immunity Poster (0992–1006)

8:30AM-10:30AM: Abstract Number: 1282

Classification of Disease Activity and Damage in Cutaneous Lupus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1107

Clinical and Genetic Features of Chinese Adult Patients with Chronic Non-bacterial Osteomyelitis: A Single Center Report

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1031

Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the United States: A Systematic Literature Review

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1306

Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1357

Clinical and Molecular Profiles Determining Cardiovascular Risk in Psoriatic Arthritis: Specific Response to Apremilast and Methotrexate

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1089

Clinical Associations of Anti-Ro52 Antibodies in Patients with Systemic Autoimmune Rheumatic Diseases

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1298

Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1310

Clinical Characteristics of Patients with SpA and Concomitant IBD: Results from the ASAS PerSpA Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1409

Clinical Features at Disease Onset of Different Subsets of Large-vessel-giant Cell Arteritis in a Monocentric Cohort of 100 Patients

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

8:30AM-10:30AM: Abstract Number: 1278

Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1227

Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1402

Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

«Previous Page
1
…
3
4
5
6
7
…
32
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].